See more : USG Tech Solutions Limited (USGTECH.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Flexion Therapeutics, Inc. (FLXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Flexion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- 10X Capital Venture Acquisition Corp. II (VCXAU) Income Statement Analysis – Financial Results
- Nabors Industries Ltd. (NBRWF) Income Statement Analysis – Financial Results
- Mediclinic International plc (MEI.JO) Income Statement Analysis – Financial Results
- Schibsted ASA (SBSNY) Income Statement Analysis – Financial Results
- Nuway Organic Naturals India Limited (NUWAY.BO) Income Statement Analysis – Financial Results
Flexion Therapeutics, Inc. (FLXN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.flexiontherapeutics.com
About Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.55M | 72.96M | 22.52M | 355.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 19.25M | 9.96M | 7.34M | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 66.30M | 63.00M | 15.19M | 351.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.50% | 86.35% | 67.43% | 98.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.33M | 69.56M | 53.08M | 51.23M | 41.31M | 32.69M | 17.92M | 11.06M | 11.07M | 8.24M |
| General & Administrative | 105.00M | 129.71M | 121.31M | 78.80M | 28.47M | 13.37M | 9.06M | 6.70M | 3.95M | 3.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 105.00M | 129.71M | 121.31M | 78.80M | 28.47M | 13.37M | 9.06M | 6.70M | 3.95M | 3.05M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 159.32M | 199.27M | 174.39M | 130.03M | 69.78M | 46.06M | 26.99M | 17.77M | 15.01M | 11.29M |
| Cost & Expenses | 178.57M | 209.23M | 181.73M | 130.04M | 69.78M | 46.06M | 26.99M | 17.77M | 15.01M | 11.29M |
| Interest Income | 876.00K | 3.21M | 4.57M | 3.72M | 1.52M | 1.25M | 478.72K | 234.00K | 193.90K | 173.29K |
| Interest Expense | 20.03M | 17.07M | 15.71M | 11.27M | 1.75M | 570.99K | 401.37K | 448.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.34M | 2.40M | 1.71M | 2.01M | 1.15M | 238.15K | 120.34K | 79.81K | 43.23K | 105.57K |
| EBITDA | -89.84M | -130.31M | -152.23M | -124.21M | -69.00M | -45.51M | -26.79M | -17.66M | -14.94M | -11.34M |
| EBITDA Ratio | -105.01% | -178.61% | -675.87% | -34,987.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.02M | -136.27M | -159.20M | -129.68M | -69.78M | -46.06M | -26.99M | -17.77M | -15.01M | -11.29M |
| Operating Income Ratio | -108.73% | -186.78% | -706.81% | -36,529.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -20.19M | -13.50M | -10.46M | -7.80M | -2.11M | -252.38K | -326.39K | -421.52K | 30.02K | -159.38K |
| Income Before Tax | -113.21M | -149.77M | -169.66M | -137.48M | -71.89M | -46.32M | -27.31M | -18.19M | -14.98M | -11.45M |
| Income Before Tax Ratio | -132.33% | -205.29% | -753.24% | -38,727.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 495.00K | 3.56M | 5.26M | 3.47M | -366.48K | 318.62K | 74.98K | 27.37K | 30.02K | -159.38K |
| Net Income | -113.71M | -149.77M | -169.66M | -137.48M | -71.89M | -46.32M | -27.31M | -18.19M | -14.98M | -11.45M |
| Net Income Ratio | -132.91% | -205.29% | -753.24% | -38,727.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.66 | -3.93 | -4.49 | -4.16 | -2.84 | -2.15 | -1.97 | -1.23 | -2.04 | -1.18 |
| EPS Diluted | -2.66 | -3.93 | -4.49 | -4.16 | -2.84 | -2.15 | -1.97 | -1.23 | -2.04 | -1.18 |
| Weighted Avg Shares Out | 42.78M | 38.09M | 37.75M | 33.03M | 25.30M | 21.50M | 13.89M | 14.75M | 7.34M | 9.74M |
| Weighted Avg Shares Out (Dil) | 42.78M | 38.09M | 37.75M | 33.03M | 25.30M | 21.50M | 13.89M | 14.75M | 7.34M | 9.74M |
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: FTS International, Inc. (NYSE: FTSI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
NEW YORK, Oct. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua...
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
Flexion Therapeutics: Bullish On The Buyout
Flexion Therapeutics recently announced that they have agreed to be acquired by Pacira BioSciences for $8.50 a share bid with the potential for an extra $8 from CVR. I provide a brief background on Pacira BioSciences and some of the...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion Therapeutics, Inc. ("Flexion" or the "Company") (NASDAQ: FLXN) in connection with the proposed acquisition...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). Stockholders...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.
New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Flexion Therapeutics, Inc. (NASDAQ: FLXN) ("Flexion Therapeutics" or the "Company") stock prior to...
Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Flexion (Nasdaq: FLXN), for possible breaches of fiduciary duty and other violations of law in its transaction with Pacira. Click here to learn how to join the action: https://www.ademilaw.com/case/flexion-therapeutics-inc or call...
Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up...
Source: https://incomestatements.info
Category: Stock Reports